Retatrutide Clinical Trials

Direct answer

Retatrutide clinical-trial records are research-status information. They do not show that retatrutide is approved, available by prescription, available from pharmacies, or appropriate for a reader. Retatrutide remains investigational and is not FDA-approved.

The safest public source for trial status is ClinicalTrials.gov. It can show the trial sponsor, study phase, eligibility criteria, intervention, recruitment status, locations, outcomes, and update dates. It is not treatment guidance.

How to read a ClinicalTrials.gov record

Clinical trial records identify what researchers planned to study and what status the registry reports. A trial may be recruiting, active and not recruiting, completed, suspended, terminated, or withdrawn. Those statuses describe the study record, not commercial access.

A record can also include eligibility criteria, age range, health conditions, enrollment, study arms, primary outcomes, secondary outcomes, and location information. Readers should not use those details to self-select or seek retatrutide outside a legitimate trial.

Current retatrutide Phase 3 program

ClinicalTrials.gov lists retatrutide studies across obesity, overweight, type 2 diabetes, cardiovascular and kidney outcomes, and selected related conditions. Records such as "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight" and "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity" are part of larger sponsor-named trial programs, but each record has its own population, status, enrollment, estimated or actual completion dates, and outcome measures.

Those details help readers understand the research program. They do not create ordinary care access, medication availability, or personal eligibility. A recruiting trial is not the same as a prescription route. An active trial is not the same as pharmacy distribution. A completed trial is not the same as FDA approval.

What trial status does and does not mean

Recruiting means the registry reports that a trial may be enrolling participants at one or more sites. It does not mean the investigational drug is commercially available or that a reader will qualify. Trial routing and eligibility evaluation belong with official trial sites and clinicians.

Active, not recruiting means the study is ongoing but not enrolling new participants. Completed means the trial record reports that the study has ended. It does not mean the results are published, that FDA has reviewed the data, or that a product is approved. Estimated dates should be treated as estimates, and actual dates should still not be treated as approval milestones.

Sponsor-reported results versus approval

Lilly has reported topline Phase 3 results for the ClinicalTrials.gov record titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight," also known as TRIUMPH-1. That information can be summarized only as sponsor-reported trial information. It is not FDA approval, not prescribing information, and not a public product label.

Sponsor-reported percentages are not personal expectations. They do not mean a reader will lose a specific amount of weight or that retatrutide should be requested from a clinician. The next regulatory question is whether the sponsor submits data and whether FDA reviews and approves a product label.

Trial status is not access

Many readers look at trial records because they are trying to understand when a medicine might become available. That is understandable, but trial-status education is different from a participation funnel, provider directory, or access explainer.

Eligibility interpretation, contact scripts, site recommendations, sourcing claims, and advice about how to obtain investigational medication belong outside public education. Official trial records are the public source, and personal medical questions belong with licensed clinicians and official study staff.

What trial participation means

Clinical trial participation is governed by a protocol, eligibility criteria, informed consent, study monitoring, and investigational-drug controls. It is not the same as routine clinical care or pharmacy access.

A patient interested in clinical trials should use official trial records and discuss eligibility questions with the trial site or their clinician. Trial matching, provider matching, and investigational-drug sourcing are not part of research-status education.

Research status only

Retatrutide information is limited to source-dated research and regulatory status. Clinical use, personal eligibility, dosing, administration, symptom management, pharmacy access, provider access, and product sourcing are not available without FDA approval and labeling.

If retatrutide is approved in the future, FDA approval materials and product labeling become the source for patient-use language.

Source currency

Retatrutide status depends on FDA pages, ClinicalTrials.gov registry records, peer-reviewed publications when available, and clearly labeled sponsor-reported releases.

A registry record, trial acronym, press release, or estimated completion date is not FDA approval and is not a prescription, pharmacy, provider, price, or access signal.

Selected retatrutide Phase 3 records checked for review

Questions